I was very pleased to read this article and glad to share it.
The CD12 results were very good, demonstrating (again) that leronlimab works.
The subgroup analysis certainly is not appropriate for approval (this trial ended more as 2b than 3 with the small size of critical group and heterogeneous trial population), but these results are exactly what the world needs and the purpose for EUAs (not for do little to nothing drugs like remdesivir).
I am certain the FDA will be hearing from many doctors and patients' families.
Market Data 
Markets 
AI
